A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability

Toxicology

Volumn 319, Issue 1, 2014, Pages 53-62

  Nagai, Noriaki ^a   Ito, Yoshimasa ^a   Okamoto, Norio ^a   Shimomura, Yoshikazu ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Corneal toxicity; Eye drops; Indomethacin; Nanoparticle; Transcorneal penetration

Indexed keywords

BROMFENAC; BRONUK; DICLOFENAC; INDOMETACIN; NEPAFENAC; PRANOPROFEN; UNCLASSIFIED DRUG; ZIRCONIUM OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA PERMEABILITY; CORNEAL TOXICITY; DEBRIDEMENT; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG TOLERABILITY; EYE TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; WOUND HEALING;

CORNEAL TOXICITY; EYE DROPS; INDOMETHACIN; NANOPARTICLE; TRANSCORNEAL PENETRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIAL LOAD; BENZALKONIUM COMPOUNDS; BETA-CYCLODEXTRINS; CELL LINE; CORNEA; ESCHERICHIA COLI; HUMANS; INDOMETHACIN; MALE; MANNITOL; METHYLCELLULOSE; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PERMEABILITY; RATS; RATS, WISTAR; WOUND HEALING; ZIRCONIUM;

EID: 84896105752     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.02.012     Document Type: Article

References (68)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with Image J. Biophotonics Int. 2004, 11:36-42.
2. Alió J.L., Sayans J.A., Chipont E. Laser flare-cell measurement of inflammation after uneventful extracapsular cataract extraction and intraocular lens implantation. J. Cataract Refract. Surg. 1996, 22:775-779.
3. Ammar H.O., Salama H.A., Ghorab M., Mahmoud A.A. Nanoemulsions as potential ophthalmic delivery systems for orzolamide hydrochloride. AAPS Pharm. Sci. Technol. 2009, 10:808-819.
4. Araki-Sasaki K., Ohashi Y., Sasabe T., Hayashi K., Watanabe H., Tano Y., Handa H. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci. 1995, 36:614-621.
5. Araújo J., Gonzalez E., Egea M.A., Garcia M.L., Souto E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009, 5:394-401.
6. Asasutjarit R., Thanasanchokpibull S., Fuongfuchat A., Veeranodha S. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. Int. J. Pharm. 2011, 411:128-135.
7. Burstein N.L. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest. Ophthalmol. Vis. Sci. 1980, 19:308-313.
8. Calvo P., Alonso M., Vila-Jato J.L., Robinson J.R. Improved ocular bioavailability of indomethacin by ocular drug carriers. J. Pharm. Phaemacol. 1996, 48:1147-1152.
9. Camras C.B., Miranda O.C. The putative role of prostaglandins in surgical miosis. Prog. Clin. Biol. Res. 1989, 312:197-210.
10. Casolaro M., Casolaro I., Lamponi S. Stimuli-responsive hydrogels for controlled pilocarpine ocular delivery. Eur. J. Pharm. Biopharm. 2012, 80:553-561.
11. Chung S.H., Lee S.K., Cristol S.M., Lee D.W., Seo K.Y., Kim E.K. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol. Vis. 2006, 12:415-421.
12. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 1991, 8:713-720.
13. Comstock T.L., Paterno M.R., Singh A., Erb T., Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin. Ophthalmol. 2011, 5:177-186.
14. Davies N.M., Fair S.J., Hadgraft J., Kellaway I.W. Evaluation of mucoadhesive polymers in ocular drug delivery. I: Viscous solutions. J. Pharm. Sci. 1991, 8:1039-1043.
15. Debbasch C., Brignole F., Pisella P.J., Warnet J.M., Rat P., Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 2001, 42:642-652.
16. Debbasch C., Pisella P.J., De Saint Jean M., Rat P., Warnet J.M., Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 2001, 42:2525-2533.
17. De Saint Jean M., Brignole F., Bringuier A.F. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 1999, 40:619-630.
18. De Saint Jean M., Debbasch C., Brignole F., Rat P., Warnet J.M., Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr. Eye Res. 2000, 20:85-94.
19. Diebold Y., Jarrin M., Saez V., Carvalho E.L.S., Orea M., Calonge M., Seijo B., Alonso M.J. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007, 28:1553-1564.
20. Dubé P., Boisjoly H.M., Bazin R., Chamberland G., Laughrea P.A., Dubé I. Comparison of prednisolone acetate and indomethacin for maintaining mydriasis during cataract surgery. Can. J. Ophthalmol. 1990, 25:234-238.
21. El-Kamel A.H. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 2002, 241:47-55.
22. Guenoun J.M., Baudouin C., Rat P., Pauly A., Briqnole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 2005, 46:4594-4599.
23. Guenoun J.M., Baudouin C., Rat P., Pauly A., Warnet J.M., Briqnole Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 2005, 46:2444-2450.
24. Gupta H., Aqil M., Khar R.K., Ali A., Bhatnagar A., Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J. Drug Target 2011, 19:409-417.
25. Gupta D., Tator C.H., Shoichet M.S. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006, 27:2370-2379.
26. Ito Y., Nagai N., Shimomura Y. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit. Biol. Pharm. Bull. 2010, 33:1574-1578.
27. Iwata S., Osada Y., Ogino H. Aspect on corneal permeability of bupranolol. Yakugaku Zassi 1980, 100:402-406.
28. Jansen T., Xhonneux B., Mesens J., Borgers M. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res. 1990, 7:459-468.
29. Korenfeld M.S., Silverstein S.M., Cooke D.L., Vogel R., Crockett R.S. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J. Cataract Refract. Surg. 2008, 35:26-34.
30. Kundu P.P., Kundu M. Effect of salts and surfactant and their doses on the gelation of extremely dilute solutions of methyl cellulose. Polymer 2001, 42:2015-2020.
31. Kuppens E.V., de Jong C.A., Stolwijk T.R., De Keizer R.J., Van Best J.A. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br. J. Ophthalmol. 1995, 79:339-342.
32. Laurell C.G., Zetterström C., Philipson B., Syrén-Nordqvist S. Randomized study of the blood-aqueous barrier reaction after phacoemulsification and extracapsular cataract extraction. Acta Ophthalmol. Scand. 1998, 76:573-578.
33. Li X., Zhang Z., Li J., Sun S., Weng Y., Chen H. Diclofenac/biodegradable polymer micelles for ocular applications. Nanoscale 2012, 4:4667-4673.
34. Lin C.P., Boehnke M. Influences of methylcellulose on corneal epithelial wound healing. J. Ocul. Pharmacol. Ther. 1999, 15:59-63.
35. Lin Y., Sun J., Jiang G., Zan J., Ding F. In vitro evaluation of lysozyme-loaded microspheres in thermosensitive methylcellulose- based hydrogel. Chinese J. Chem. Eng. 2007, 15:566-572.
36. Lorenz K., Dick B., Jehkul A., Auffahrt G.U. Inflammatory response after phacoemulsification treated with 0.5% prednisolone acetate or vehicle. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1617-1622.
37. McGhee C.N., Dean S., Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002, 25:33-55.
38. Meisner D., Pringle J., Mezei M. Liposomal ophthalmic drug delivery. III: Pharmacodynamic and biodisposition studies of atropine. Int. J. Pharm. 1989, 55:105-113.
39. Miyake K. Studies on clinical pathophysiology of pseudophakic/aphakic eyes-a journey of 4 decades. Nippon Ganka Gakkai Zasshi 2008, 112:214-246.
40. Miyake K., Sugiyama S., Norimatsu I., Ozawa T. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III) radioimmunoassay measurement of prostaglandins in aqueous humor during and after lens extraction procedures. Graefe's Arch. Clin. Exp. Ophthalmol. 1978, 209:83-88.
41. Mochizuki M., Sawa M., Masuda K. Topical indomethacin in intracapsular extraction of senile cataract. Jpn. J. Ophthalmol. 1977, 21:215-226.
42. Mori K., Yoshioka N., Kondo Y., Takeuchi T., Yamashita H. Catalytically active, magnetically separable, and water-soluble FePt nanoparticles modified with cyclodextrin for aqueous hydrogenation reactions. Green Chem. 2009, 11:1337-1342.
43. Muchtar S., Abdulrazik M., Pery J.F., Benita S. Ex vivo permeation study of indomethacin from a submicron emulsion through albino cornea. J. Control. Release 1997, 44:55-64.
44. Mueller W.H., Deardorff D.L. Ophthalmic vehicles: the effect of methylcellulose on the penetration of homatropine hydrobromide through the cornea. J. Am. Pharm. Assoc. 1956, 45:334-341.
45. Nagai N., Ito Y. Therapeutic effects of gel ointments containing tranilast nanoparticles on paw edema in adjuvant-induced arthritis rats. Biol. Pharm. Bull. 2014, 37:96-104.
46. Nagai N., Ito Y., Okamoto N., Shimomura Y. Decrease in corneal damage due to benzalkonium chloride by the addition of sericin into timolol maleate eye drops. J. Oleo Sci. 2013, 62:159-166.
47. Nagai N., Murao T., Ito Y., Okamoto N., Sasaki M. Enhancing effects of sericin on corneal wound healing in rat debrided corneal epithelium. Biol. Pharm. Bull. 2009, 32:933-936.
48. Nagai N., Murao T., Oe K., Ito Y., Okamoto N., Shimomura Y. In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T). Yakugaku Zasshi 2011, 131:985-991.
49. Nagai N., Ono H., Hashino M., Ito Y., Okamoto N., Shimomura Y. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles. J. Oleo Sci. 2014, 63:177-186.
50. Nichols J., Snyder R.W. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr. Opin. Ophthalmol. 1998, 9:40-44.
51. Okamoto N., Ito Y., Nagai N., Murao T., Takiguchi Y., Kurimoto T., Mimura O. Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea. J. Oleo Sci. 2010, 59:423-430.
52. Pande M.V., Spalton D.J., Kerr-Muir M.G., Marshall J. Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. J. Cataract Refract. Surg. 1996, 22:770-774.
53. Pisella P.J., Fillacier K., Elena P.P., Debbasch C., Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000, 32:3-8.
54. Podos S.M. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans. Am. Ophthalmol. Soc. 1976, 74:637-660.
55. Rafie F., Javadzadeh Y., Javadzadeh A.R., Ghavidel L.A., Jafari B., Moogooee M., Davaran S. In vivo evaluation of novel nanoparticles containing dexa-methasone for ocular drug delivery on rabbit eye. Curr. Eye Res. 2010, 35:1081-1089.
56. Rolando M., Brezzo G., Giordano P., Campagna P., Burlando S., Calabria G. The Lacrimal System 1991, 89-91. Kagler and Ghedini, Amsterdam. O.P. Van Bijsterweld, M.A. Lemp, D. Spinelli (Eds.).
57. Sanders D.R., Kraff M.C., Lieberman H.L., Peyman G.A., Tarabishy S. Breakdown and reestablishment of blood-aqueous barrier with implant surgery. Arch. Ophthalmol. 1982, 100:588-590.
58. Sanz T., Fernandez M.A., Salvador A., Munoz J., Fiszman S.M. Thermogelation properties of methylcellulose (MC) and their effect on a batter formula. Food Hydrocolloids 2005, 19:141-147.
59. ®-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv. 2006, 13:215-219.
60. Tate M.C., Shear D.A., Hoffman S.W., Stein D.G., LaPlaca M.C. Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 2001, 22:1113-1123.
61. Toropainen E., Ranta V.P., Vellonen K.S., Palmgrén J., Talvitie A., Laavola M., Suhonen P., Hämäläinen K.M., Auriola S., Urtti A. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. Eur. J. Pharm. Sci. 2003, 20:99-106.
62. Tomoda K., Terashima H., Suzuki K., Inagi T., Terada H., Makino K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf. B: Biointerfaces 2011, 88:706-710.
63. Tomoda K., Terashima H., Suzuki K., Inagi T., Terada H., Makino K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo. Colloids Surf. B: Biointerfaces 2012, 92:50-54.
64. Tomoda K., Watanabe A., Suzuki K., Inagi T., Terada H., Makino K. Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis. Colloids Surf. B: Biointerfaces 2012, 97:84-89.
65. Wells M.R., Kraus K., Batter D.K., Blunt D.G., Weremowitz J., Lynch S.E., Antoniades H.N., Hansson H.A. Gel matrix vehicles for growth factor application in nerve gap injuries repaired with tubes: a comparison of biomatrix, collagen, and methylcellulose. Exp. Neurol. 1997, 146:395-402.
66. Wilson W.S., Duncan A.J., Jay J.L. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br. J. Ophthalmol. 1975, 59:667-669.
67. Yakuji Nippo Ltd. Japanese Pharmacopoeia 2011, 16. Maruzen Co. Ltd., Tokyo.
68. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 1981, 4:879-885.